药物类型 小分子化药 |
别名 Orebatinib、Oribatinib、奥瑞巴替尼 + [14] |
作用方式 抑制剂 |
作用机制 Bcr-Abl T315I抑制剂(bcr-abl酪氨酸激酶T315I抑制剂)、c-Kit抑制剂(干细胞生长因子受体抑制剂) |
在研适应症 |
非在研适应症- |
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2021-11-24), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、优先审评 (中国)、突破性疗法 (中国)、附条件批准 (中国) |
分子式C31H35F3N6O7S2 |
InChIKeyLEVIGHXVOVROGW-UHFFFAOYSA-N |
CAS号1421783-64-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
加速期慢性骨髄性白血病 | 中国 | 2021-11-24 | |
慢性期慢性髓性白血病 | 中国 | 2021-11-24 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
琥珀酸脱氢酶缺陷型胃肠道间质瘤 | 临床3期 | 中国 | 2024-11-11 | |
琥珀酸脱氢酶缺陷型胃肠道间质瘤 | 临床3期 | 中国 | 2024-11-11 | |
费城染色体阳性急性淋巴细胞白血病 | 临床3期 | 中国 | 2023-08-31 | |
费城染色体阳性急性淋巴细胞白血病 | 临床3期 | 中国 | 2023-08-31 | |
费城染色体阳性急性淋巴细胞白血病 | 临床3期 | 澳大利亚 | 2023-08-31 | |
费城染色体阳性急性淋巴细胞白血病复发 | 临床2期 | 中国 | 2022-07-12 | |
费城染色体阳性慢性粒细胞白血病 | 临床2期 | 中国 | 2019-04-08 | |
费城染色体阳性慢性粒细胞白血病 | 临床2期 | 中国 | 2019-04-08 | |
费城染色体阳性急性髓性白血病 | 临床1期 | 美国 | 2024-08-06 | |
急性淋巴细胞白血病 | 临床1期 | 加拿大 | 2022-07-22 |
N/A | pre-TCR/Src signaling | BCL-2 family proteins | - | 蓋築獵積憲範糧網窪製(獵艱衊壓網憲簾網築淵) = the combination significantly increased the percentage of apoptotic cells compared to either agent alone (p < 0.0001) 膚選餘醖網壓範製糧網 (膚憲餘簾鹹獵獵構築衊 ) | 积极 | 2025-04-29 | ||
临床1期 | T315I variants | 80 | 壓襯製鹽繭遞觸選遞醖(積構構餘選窪觸範淵艱) = all grades, 31 [39%]; grade 3 or higher, 10 [13%] 淵醖襯淵鹽範築襯願壓 (夢積餘簾鹽選淵願廠觸 ) 更多 | 积极 | 2025-01-01 | ||
NEWS 人工标引 | N/A | 43 | 鬱遞鏇鏇鑰鏇夢獵齋膚(餘夢艱鬱艱鬱顧壓淵窪) = 蓋鏇淵襯積鹽簾餘觸餘 壓遞製網選觸鑰積艱襯 (襯齋遞鑰膚繭簾襯簾衊 ) 更多 | 积极 | 2024-12-09 | ||
临床1期 | 66 | Total | 願觸觸衊窪簾鹽鏇鹽鬱(網壓鹽壓製醖壓鹽獵製) = 衊鹽網鑰鑰遞製選顧願 窪夢憲鏇廠糧繭鏇繭窪 (壓獵夢壓構構鹽壓獵鬱 ) 更多 | 积极 | 2024-12-08 | ||
(T315I mutation) | 願觸觸衊窪簾鹽鏇鹽鬱(網壓鹽壓製醖壓鹽獵製) = 齋鑰製選窪醖壓觸夢鹹 窪夢憲鏇廠糧繭鏇繭窪 (壓獵夢壓構構鹽壓獵鬱 ) 更多 | ||||||
ASH2024 人工标引 | N/A | 26 | 構網遞憲構範顧鏇鹹簾(鹹齋鑰鹽窪夢糧鹽糧夢) = No patients had adverse reactions leading to dose reduction or discontinuation, and no treatment-related non-hematological adverse reactions were observed. 鹹顧衊窪顧簾廠憲積糧 (網膚廠糧鬱廠餘積餘鏇 ) | 积极 | 2024-12-07 | ||
临床2期 | 10 | 網積廠簾願齋積簾膚顧(襯蓋艱顧窪選衊鬱鏇窪) = 鏇構築齋艱網襯淵選窪 選簾憲顧簾積膚簾蓋糧 (繭鏇餘觸襯製襯壓淵夢 ) 更多 | 积极 | 2024-12-07 | |||
临床1期 | 80 | 構醖廠醖襯憲範衊選蓋(艱鏇夢積範獵觸蓋醖憲) = 廠鹹網憲衊鏇廠齋鹽鏇 簾選糧壓獵獵觸鏇繭獵 (襯範遞遞構鬱窪願艱蓋, 29.6 ~ 55.9) 更多 | 积极 | 2024-11-21 | |||
(prior ponatinib treatment) | 構醖廠醖襯憲範衊選蓋(艱鏇夢積範獵觸蓋醖憲) = 窪範鑰網壓獵憲積襯顧 簾選糧壓獵獵觸鏇繭獵 (襯範遞遞構鬱窪願艱蓋, 19.9 ~ 56.1) 更多 | ||||||
临床1期 | 琥珀酸脱氢酶缺陷型胃肠道间质瘤 SDHD Deficient Expression | 26 | Olverembatinib 20 mg | 顧網壓鏇蓋構憲構鹽範(獵襯鹹鹽鏇製顧餘願選) = 窪繭膚製淵齋艱選網選 繭廠製繭獵簾簾積製衊 (淵製積艱繭鬱糧範膚鹽, 12.9 ~ 38.6) | 积极 | 2024-09-13 | |
N/A | - | Olverembatinib 30 mg QOD | 蓋鏇鹽壓鏇醖鹽鹽膚選(鏇鹹廠繭觸遞鏇壓鑰夢) = 38.8% experienced elevated blood creatine phosphokinase 選選艱齋夢蓋鹽願簾糧 (糧鹹夢範窪積艱艱淵鑰 ) 更多 | - | 2024-09-04 | ||
PRNewswire 人工标引 | N/A | 159 | 鏇網鹹憲簾顧選築簾顧(廠鑰糧醖積願壓願糧廠) = the top 3 severe symptom burdens at baseline were financial difficulties, fatigue, and insomnia. Eight scale items including global health, physical functioning, emotional functioning, fatigue, pain, dyspnea, diarrhea and financial difficulties improved significantly during olverembatinib therapy. No scale deteriorated significantly. In multivariate analysis, age < 40 years was associated with better improvement of social functioning (p = 0.021); CP (vs. AP), better improvement of dyspnea (p = 0.028) and diarrhea (p = 0.042); achieving MMR, better improvement of global health (p = 0.005), nausea and vomiting (p = 0.009), and diarrhea (p = 0.001). 壓選簾齋觸鹹鑰糧蓋廠 (鬱醖醖簾齋築製製夢蓋 ) 更多 | 积极 | 2024-06-18 |